European Commission Approves Trogarzo®

Montreal, Canada – September 26, 2019 – Theratechnologies Inc. (Theratechnologies) (TSX: TH) is pleased to announce that Trogarzo® (ibalizumab) was approved today by the European Commission. “The approval of Trogarzo® by the European Commission represents a historical milestone for Theratechnologies as it becomes our first product ever approved in that territory. We have been getting …Lire la suite

Theratechnologies Included in the First TSX30 Ranking

Montreal, Canada – September 26, 2019 – Theratechnologies Inc. (Theratechnologies) (TSX: TH) is pleased to announce that it ranked 21st on the first TSX30 ranking of top performers on the Toronto Stock Exchange. The ranking was established based on the following criteria: Corporate operating business listed on TSX on June 30, 2019 Listed on TSX …Lire la suite

Theratechnologies Reaches Agreement with AIDS Drug Assistance Program (ADAP) for New Egrifta SVTM

Montreal, Canada – September 19, 2019 – Theratechnologies Inc. (TSX: TH) is pleased to announce that an agreement has been reached with the AIDS Drug Assistance Program Crisis Task Force for EGRIFTA SVTM (tesamorelin for injection), which will commercially launch in the United States very shortly. The agreement will help to facilitate access to low …Lire la suite